Intrust Bank’s Supernus Pharmaceuticals SUPN Stock Holding History

Intrust Bank’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,438	Closed	-$274K	–	391
2018 Q3	$274K	Sell	5,438 -2,485	-31%	-$123K	0.07%	317
2018 Q2	$474K	Buy	7,923 +159	+2%	+$8.24K	0.13%	204
2018 Q1	$356K	Buy	7,764 +811	+12%	+$33.8K	0.1%	255
2017 Q4	$277K	Sell	6,953 -4	-0.1%	-$158	0.08%	310
2017 Q3	$278K	Buy	6,957 +1,901	+38%	+$82.3K	0.09%	309
2017 Q2	$218K	Buy	+5,056	New	+$180K	0.07%	356

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Intrust Bank's SUPN Position: Q4 2018 in Review

Intrust Bank sold out of Supernus Pharmaceuticals (SUPN) in Q4 2018, closing a stake of 5,438 shares — an estimated $274K sold.

Intrust Bank first reported a position in SUPN in Q2 2017 and held it in 6 quarters. The position peaked at $474K in Q2 2018. 274 funds tracked by Wall St. Rank hold SUPN as of Q4 2018.

Intrust Bank reported no remaining Supernus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Intrust Bank sold 5,438 Supernus Pharmaceuticals shares in Q4 2018, an estimated $274K.
Intrust Bank first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 6 quarters.
Intrust Bank's Supernus Pharmaceuticals position peaked at $474K in Q2 2018.
274 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2018.

Based on Intrust Bank's 13F filing for Q4 2018, filed 6 Feb 2019.